Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, the Melvin Berlin Family Chair in Multiple Myeloma, and chief attending of adult bone marrow transplant service at Memorial Sloan Kettering Cancer Center, discusses the role of allogeneic hematopoietic cell therapy (HCT) in patients with multiple myeloma.

Giralt says this is a valid option for patients and should not be dismissed. This option has been available to patients for over 2 decades, though experts are aware that the results aren’t exactly what they hope. A number of clinical trials are exploring allogeneic HCT to improve the outcomes for these patients.

In particular, allogenic HCT provides a chance for long-term disease control in younger patients who have experienced multiple relapses.

2019 Transplantation and Cellular Therapy Meetings

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Transplantation and Cellular Therapy Meetings

Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.

Dr. Giralt on Allogeneic HCT in Multiple Myeloma